These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 12230093)

  • 1. Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma.
    Sasaki M; Kuwabara Y; Koga H; Nakagawa M; Chen T; Kaneko K; Hayashi K; Nakamura K; Masuda K
    Ann Nucl Med; 2002 Jul; 16(5):337-45. PubMed ID: 12230093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 18F-FDG PET is superior to 67Ga SPECT in the staging of non-Hodgkin's lymphoma.
    Yamamoto F; Tsukamoto E; Nakada K; Takei T; Zhao S; Asaka M; Tamaki N
    Ann Nucl Med; 2004 Sep; 18(6):519-26. PubMed ID: 15515753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 18FDG PET versus high-dose 67Ga scintigraphy for restaging and treatment follow-up of lymphoma patients.
    Van Den Bossche B; Lambert B; De Winter F; Kolindou A; Dierckx RA; Noens L; Van De Wiele C
    Nucl Med Commun; 2002 Nov; 23(11):1079-83. PubMed ID: 12411836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma.
    Shen YY; Kao A; Yen RF
    Oncol Rep; 2002; 9(2):321-5. PubMed ID: 11836600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of FDG-PET in malignant lymphoma.
    Becherer A; Jaeger U; Szabo M; Kletter K
    Q J Nucl Med; 2003 Mar; 47(1):14-21. PubMed ID: 12714950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of high-risk melanoma: comparison of [18F]FDG PET and high-dose 67Ga SPET.
    Kalff V; Hicks RJ; Ware RE; Greer B; Binns DS; Hogg A
    Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):506-15. PubMed ID: 11914889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma.
    Kostakoglu L; Leonard JP; Kuji I; Coleman M; Vallabhajosula S; Goldsmith SJ
    Cancer; 2002 Feb; 94(4):879-88. PubMed ID: 11920454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Staging in childhood lymphoma: differences between FDG-PET and CT.
    Hermann S; Wormanns D; Pixberg M; Hunold A; Heindel W; Jürgens H; Schober O; Franzius C
    Nuklearmedizin; 2005 Feb; 44(1):1-7. PubMed ID: 15711722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness of 67Ga scintigraphy in extranodal malignant lymphoma patients.
    Nishiyama Y; Yamamoto Y; Toyama Y; Satoh K; Nagai M; Ohkawa M
    Ann Nucl Med; 2003 Dec; 17(8):657-62. PubMed ID: 14971607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of attenuation correction for fluorine-18 fluorodeoxyglucose positron emission tomography in the primary staging of malignant lymphoma.
    Kotzerke J; Guhlmann A; Moog F; Frickhofen N; Reske SN
    Eur J Nucl Med; 1999 Jan; 26(1):31-8. PubMed ID: 9933659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gallium-67 scintigraphy in lymphoma: is there a benefit of image fusion with computed tomography?
    Chajari M; Lacroix J; Peny AM; Chesnay E; Batalla A; Henry-Amar M; Delcambre C; Génot JY; Fruchard C; Bardet S
    Eur J Nucl Med Mol Imaging; 2002 Mar; 29(3):380-7. PubMed ID: 12002715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical value of FDG PET using coincident gamma cameras in staging and restaging of malignant lymphoma--compared with convenitonal diagnostic methods].
    Pichler R; Maschek W; Hatzl-Griesenhofer M; Huber H; Wimmer G; Wahl G; Fridrik M
    Nuklearmedizin; 2000 Sep; 39(6):166-73. PubMed ID: 11057408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluorine-18 fluorodeoxyglucose PET-CT for extranodal staging of non-Hodgkin and Hodgkin lymphoma.
    Ömür Ö; Baran Y; Oral A; Ceylan Y
    Diagn Interv Radiol; 2014; 20(2):185-92. PubMed ID: 24412817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification.
    Tsukamoto N; Kojima M; Hasegawa M; Oriuchi N; Matsushima T; Yokohama A; Saitoh T; Handa H; Endo K; Murakami H
    Cancer; 2007 Aug; 110(3):652-9. PubMed ID: 17582800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging.
    Moog F; Bangerter M; Diederichs CG; Guhlmann A; Kotzerke J; Merkle E; Kolokythas O; Herrmann F; Reske SN
    Radiology; 1997 Jun; 203(3):795-800. PubMed ID: 9169707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDG PET in the management of lymphoma: a clinical perspective.
    Hoskin PJ
    Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):449-51. PubMed ID: 11914880
    [No Abstract]   [Full Text] [Related]  

  • 17. Imaging of malignant lymphomas with F-18 FDG coincidence detection positron emission tomography.
    Hwang K; Park CH; Kim HC; Kim H; Yoon S; Pai M; Kim S
    Clin Nucl Med; 2000 Oct; 25(10):789-95. PubMed ID: 11043718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of whole-body (18)F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma.
    Schöder H; Meta J; Yap C; Ariannejad M; Rao J; Phelps ME; Valk PE; Sayre J; Czernin J
    J Nucl Med; 2001 Aug; 42(8):1139-43. PubMed ID: 11483671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positron emission tomography (PET) for staging low-grade non-Hodgkin's lymphomas (NHL).
    Najjar F; Hustinx R; Jerusalem G; Fillet G; Rigo P
    Cancer Biother Radiopharm; 2001 Aug; 16(4):297-304. PubMed ID: 11603000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18F-FDG-PET in patients with malignant lymphoma having long-term follow-up: staging and restaging, and evaluation of treatment response and recurrence.
    Isohashi K; Tatsumi M; Higuchi I; Inoue A; Nakajo K; Ishikawa J; Shimosegawa E; Kanakura Y; Nakamura H; Hatazawa J
    Ann Nucl Med; 2008 Nov; 22(9):795-802. PubMed ID: 19039558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.